"Beyond The Blues" is a collection of some of the finest musicians in the Chicago area forming a modern R&B Blues based band that goes "beyond" in the traditional sense of the genre.
Less than 4% of the NCI (National Cancer Institute) budget goes towards pediatric cancer research.
Approximately 200 kids per year in the U.S.A. are diagnosed with
Ewing's Sarcoma.
If the cancer has metastasized (spread to other parts of the body), the five-year survival rate is approximately 15-30%.
Limited Treatment Options: Despite improvements in treatment outcomes, current therapies for Ewing's sarcoma are often aggressive and can have significant side effects. There is a need for more targeted and effective treatments that can improve survival rates while minimizing long-term complications.
Drug Development: Funding is needed to support the development of new drugs and therapies specifically designed to treat Ewing's sarcoma. This includes preclinical research to identify promising drug candidates and clinical trials to evaluate their safety and efficacy in patients.
Improving Diagnosis and Prognosis: Research efforts can also focus on improving methods for diagnosing Ewing's sarcoma at an early stage and predicting patient outcomes. This can lead to better risk stratification and treatment planning, ultimately improving survival rates and quality of life for patients.
Supporting Clinical Trials: Clinical trials are essential for testing new treatments and advancing the standard of care for Ewing's sarcoma patients. However, conducting clinical trials requires significant resources, including funding for patient recruitment, treatment, and follow-up.
Overall, raising money for Ewing's sarcoma research is critical for advancing our understanding of the disease, developing more effective treatments, and ultimately improving outcomes for patients affected by this rare cancer.
